Where Does Avastin Go From Here: Moving Beyond The C-08 Failure
Executive Summary
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
You may also be interested in...
C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say
ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert
C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say
ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert
Roche Checks Wallet As Important Avastin Trial Flops
Did Roche overpay for Genentech? Closely watched adjuvant trial for colon cancer fails to meet primary endpoint.